CLCF1, AEPB1, and OS9 in the PTEN-mut subgroup are the optimal and independent prognostic signatures and can be used as potential targets for the diagnosis, prediction, and treatment of PTEN-mut glioma. Here, OS9 is linked to central nervous system cancer.